Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.

Timmermand OV, Ulmert D, Evans-Axelsson S, Pettersson K, Bjartell A, Lilja H, Strand SE, Tran TA.

EJNMMI Res. 2014 Dec;4(1):51. doi: 10.1186/s13550-014-0051-5. Epub 2014 Sep 19.

2.

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.

Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, Vickers A.

BMJ. 2014 Mar 28;348:g2296. doi: 10.1136/bmj.g2296.

3.

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H.

BMC Med. 2014 Feb 11;12:26. doi: 10.1186/1741-7015-12-26.

4.

Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle.

Thorek DL, Ulmert D, Diop NF, Lupu ME, Doran MG, Huang R, Abou DS, Larson SM, Grimm J.

Nat Commun. 2014;5:3097. doi: 10.1038/ncomms4097.

5.

REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer.

Svensson C, Ceder J, Iglesias-Gato D, Chuan YC, Pang ST, Bjartell A, Martinez RM, Bott L, Helczynski L, Ulmert D, Wang Y, Niu Y, Collins C, Flores-Morales A.

Nucleic Acids Res. 2014 Jan;42(2):999-1015. doi: 10.1093/nar/gkt921. Epub 2013 Oct 24.

6.

Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.

Thorek DL, Evans MJ, Carlsson SV, Ulmert D, Lilja H.

Thromb Haemost. 2013 Sep;110(3):484-92. doi: 10.1160/TH13-04-0275. Epub 2013 Aug 1. Review.

7.

Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging.

Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P.

J Natl Cancer Inst. 2013 Sep 4;105(17):1306-13. doi: 10.1093/jnci/djt175. Epub 2013 Jul 23.

8.

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.

Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Björk T, Gerdtsson A, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Lilja H.

BMJ. 2013 Apr 15;346:f2023. doi: 10.1136/bmj.f2023.

9.

Smoking and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition.

Rohrmann S, Linseisen J, Allen N, Bueno-de-Mesquita HB, Johnsen NF, Tjønneland A, Overvad K, Kaaks R, Teucher B, Boeing H, Pischon T, Lagiou P, Trichopoulou A, Trichopoulos D, Palli D, Krogh V, Tumino R, Ricceri F, Argüelles Suárez MV, Agudo A, Sánchez MJ, Chirlaque MD, Barricarte A, Larrañaga N, Boshuizen H, van Kranen HJ, Stattin P, Johansson M, Bjartell A, Ulmert D, Khaw KT, Wareham NJ, Ferrari P, Romieux I, Gunter MJ, Riboli E, Key TJ.

Br J Cancer. 2013 Feb 19;108(3):708-14. doi: 10.1038/bjc.2012.520. Epub 2012 Nov 20.

10.
11.

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.

Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyers CL.

Cancer Discov. 2012 Apr;2(4):320-7. doi: 10.1158/2159-8290.CD-11-0316. Epub 2012 Mar 31.

12.

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.

Evans-Axelsson S, Ulmert D, Örbom A, Peterson P, Nilsson O, Wennerberg J, Strand J, Wingårdh K, Olsson T, Hagman Z, Tolmachev V, Bjartell A, Lilja H, Strand SE.

Cancer Biother Radiopharm. 2012 May;27(4):243-51. doi: 10.1089/cbr.2011.1088. Epub 2012 Apr 10.

13.

A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.

Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Björk T, Gerdtsson A, Bjartell A, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Richter J, Sadik M, Morris MJ, Scher HI, Sjöstrand K, Yu A, Suurküla M, Edenbrandt L, Larson SM.

Eur Urol. 2012 Jul;62(1):78-84. doi: 10.1016/j.eururo.2012.01.037. Epub 2012 Jan 27.

14.

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.

Klein RJ, Hallden C, Gupta A, Savage CJ, Dahlin A, Bjartell A, Manjer J, Scardino PT, Ulmert D, Wallström P, Vickers AJ, Lilja H.

Eur Urol. 2012 Mar;61(3):471-7. doi: 10.1016/j.eururo.2011.10.047. Epub 2011 Nov 7.

15.

Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome.

Syed Khaja AS, Helczynski L, Edsjö A, Ehrnström R, Lindgren A, Ulmert D, Andersson T, Bjartell A.

PLoS One. 2011;6(10):e26539. doi: 10.1371/journal.pone.0026539. Epub 2011 Oct 24.

16.

High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.

Jonsson L, Gaber A, Ulmert D, Uhlén M, Bjartell A, Jirström K.

Diagn Pathol. 2011 Sep 28;6:91. doi: 10.1186/1746-1596-6-91.

17.

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.

Vickers AJ, Gupta A, Savage CJ, Pettersson K, Dahlin A, Bjartell A, Manjer J, Scardino PT, Ulmert D, Lilja H.

Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):255-61. doi: 10.1158/1055-9965.EPI-10-1003. Epub 2010 Dec 8.

18.

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.

Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, Bjartell AS, Scardino PT, Ulmert D, Vickers AJ.

Cancer. 2011 Mar 15;117(6):1210-9. doi: 10.1002/cncr.25568. Epub 2010 Oct 19.

19.

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Vickers AJ, Cronin AM, Björk T, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Ulmert D, Lilja H.

BMJ. 2010 Sep 14;341:c4521. doi: 10.1136/bmj.c4521.

20.

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.

Savage CJ, Lilja H, Cronin AM, Ulmert D, Vickers AJ.

Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1201-7. doi: 10.1158/1055-9965.EPI-09-1251. Epub 2010 Apr 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk